We are live on ! Find out more
ANIX icon

Anixa Biosciences
ANIX

14 hedge funds and large institutions have $169K invested in Anixa Biosciences in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,584,600% more capital inflows, than outflows

Capital inflows: $25.8K | Capital outflows: $1

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

27% more funds holding

Funds holding: 11 → 14 (+3)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.5% less ownership

Funds ownership: 1.48% → 0.98% (-0.5%)

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Virtu KCG Holdings
Virtu KCG Holdings
New York
+$17.4K
2
UBS Group
UBS Group
Switzerland
+$5.7K
3
IFP Advisors
IFP Advisors
Florida
+$1.39K
4
JP Morgan Chase
JP Morgan Chase
New York
+$1.24K
5
Bank of America
Bank of America
North Carolina
+$111

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1

ANIX Hedge Fund Activity: Q2 2017 in Review

14 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q2 2017, worth a combined $169K — down 56% from $385K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ANIX positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $17.4K. The largest seller was Vanguard Group, cutting an estimated $1.

  • 14 institutional investors held Anixa Biosciences (ANIX) as of Q2 2017, up from 11 in Q1 2017.
  • Funds reported $169K of Anixa Biosciences stock for Q2 2017, down 56% quarter-over-quarter.
  • 4 funds opened new Anixa Biosciences positions in Q2 2017 and 1 closed out, a net change of +3 holders.
  • The largest Anixa Biosciences buyer in Q2 2017 was Virtu KCG Holdings, an estimated $17.4K added.
  • The largest Anixa Biosciences seller in Q2 2017 was Vanguard Group, an estimated $1 sold.

Based on aggregated 13F filings for Q2 2017.